Abstract The cytochrome p450 family 19 gene (CYP19A1) encodes for aromatase, which catalyzes the final step in estrogen biosynthesis and conversion of androgens to estrogens. Genetic variation in CYP19A1 is linked to higher circulating estrogen levels and increased aromatase expression. Using data from the Breast Cancer Health Disparities Study, a consortium of three population-based case-control studies in the United States (n = 3,030 non-Hispanic Whites; n = 2,893 Hispanic/Native Americans (H/NA) and Mexico (n = 1,810), we examined influence of 25 CYP19A1 tagging single-nucleotide polymorphisms (SNPs) on breast cancer risk and mortality, considering NA ancestry. Odds ratios (ORs) and 95 % confidence intervals (CIs) and hazard ratios estimated breast cancer risk and mortality. After multiple comparison adjustment, none of the SNPs were significantly associated with breast cancer risk or mortality. Two SNPs remained significantly associated with increased breast cancer risk in women of moderate to high NA ancestry (C29 %): rs700518, OR GG 1.36, 95 % CI 1.11-1.67 and rs11856927, OR GG 1.35, 95 % CI 1.05-1.72. A significant interaction was observed for rs2470144 and menopausal status (p adj = 0.03); risk was increased in postmenopausal (OR AA 1.22, 95 % CI 1.05-1.14), but not premenopausal (OR AA 0.78, 95 % CI 0.64-0.95) women. The absence of an overall association with CYP19A1 and breast cancer risk is similar to previous literature. However, this analysis provides support that variation in CYP19A1 may influence breast cancer risk differently in women with moderate to high NA ancestry. Additional research is warranted to investigate the how variation in an estrogen-regulating gene contributes to racial/ethnic disparities in breast cancer.
Introduction
The cytochrome p450 family 19 gene (CYP19A1), located on chromosome 15, encodes for the enzyme aromatase, which catalyzes the final step in estrogen biosynthesis and metabolism converting androgens to estrogens, in the ovaries of premenopausal women and primarily in the adipose tissue of postmenopausal women [1, 2] . Genetic variation in the aromatase gene makes an attractive candidate to evaluate as a breast cancer risk factor due to this gene's involvement in the regulation of endogenous estrogen and to the recognized association between estrogen exposure levels in blood and urine and breast cancer risk [3] [4] [5] . During breast carcinogenesis, estrogen interacts with the cell cycle promoting cellular division and proliferation [6] . Estrogen may also act locally in surrounding adipose tissue to promote the growth of breast cancer [7] . Additionally, while clinical data are in agreement with an anti-invasive effect of estrogens, disruptions in the estrogen receptor-signaling pathway could lead to metastasis [8, 9] .
Single-nucleotide polymorphisms (SNPs) in CYP19A1 have been shown to be associated with circulating estrogen levels; specifically rs727479 (T), rs10046 (T), and rs4646 (G), while rs700518 (G/A at Val 80 , located in exon 3) was found to be associated with increased aromatase expression [10] [11] [12] [13] [14] . Despite this relationship, epidemiological studies have shown mixed results for an association between SNPs in CYP19A1 and breast cancer risk [10, 11, 13, [15] [16] [17] [18] [19] [20] . Likewise, epidemiological studies to date show inconsistent associations between SNPs in CYP19A1 and breast cancer mortality [21] [22] [23] [24] [25] [26] . Moreover, none of these studies have included Hispanic women; a genetically admixed population with European, Native American (NA), and African ancestry [27, 28] . In the USA and Mexico, Hispanic women with a higher proportion of European ancestry were found to have a higher risk of breast cancer [28, 29] . Additionally, previous findings suggest that the proportion of NA ancestry modifies the direction and strength of associations between reported genetic variants involved in hormones and breast cancer risk and mortality, and may contribute to the observed racial differences in breast cancer incidence and survival [28, 30] . It is plausible that gene-environment interactions involving hormonal pathways may also play a role in these differences, particularly given the observed variation by race in distributions of hormone receptor status, hormone-related risk factors, and genetic factors [31] [32] [33] [34] [35] [36] .
In this study, we conducted a comprehensive evaluation of associations between CYP19A1 polymorphisms and breast cancer risk and breast cancer mortality using data from the Breast Cancer Health Disparities Study (BCHDS), a multicenter population-based case-control study including US non-Hispanic White (NHW), U.S. Hispanic/NA, and Mexican women. We considered potential interactions between CYP19A1 genetic variants and variables thought to influence the estrogen pathway [hormone therapy (HT) use, oral contraceptive (OC) use, menopausal status, estrogen receptor (ER), and progesterone receptor (PR) status]. Additionally, we considered possible heterogeneity of the association between CYP19A1 genetic variants and breast cancer risk and mortality by race/ethnicity and NA ancestry.
Methods

Study population
The BCHD study [28] is a consortium of three previously conducted population-based case-control studies, the 4-Corners Breast Cancer Study (4-CBCS) [37] , the San Francisco Bay Area Breast Cancer Study (SFBCS) [38, 39] , and the Mexico Breast Cancer Study (MBCS) [40] . Inperson interviews were conducted and blood or saliva samples were collected. The 4-CBCS participants were non-Hispanic White, Hispanic, or NA, between 25 and 79 years of age and included histologically confirmed breast cancer cases (in situ or invasive) with a first primary diagnosed between 10/1999 and 05/2004, and controls selected from the target populations of cases living in Arizona, Colorado, New Mexico, and Utah and were frequency-matched to cases on ethnicity and 5-year age distribution. SFBCS participants were aged 35-79 years from the San Francisco Bay Area diagnosed with a first primary histologically confirmed invasive breast cancer between 04/1995 and 04/2002 (Hispanics) or between 04/1995 and 04/1999 (NHWs); and controls were identified by randomdigit dialing and frequency-matched to cases on ethnicity and 5-year age distribution. MBCS participants were between 28 and 74 years of age: Cases were women diagnosed with a new histologically confirmed breast cancer (in situ or invasive) between 01/2004 and 12/2007 at 12 participating hospitals from three main health care systems; controls were randomly selected from the catchment area of the 12 participating hospitals using a probabilistic multistage design. All participants signed informed written consent prior to interview, and all studies were approved by their corresponding Institutional Review Board for Human Subjects.
Data harmonization
Data were harmonized across all study centers and questionnaires as previously described [28] . Women were classified as either premenopausal or postmenopausal based on responses to questions on menstrual history and hormone therapy (HT) use. Women who reported still having periods during the referent year were classified as premenopausal. Study-specific definitions were used to define postmenopausal women. Women were classified as postmenopausal if: (1) they reported a natural menopause; or (2) they reported taking HT and were still having periods and were at or above the 95th percentile of age for race/ ethnicity of those who reported having a natural menopause (i.e., [12 months since their last period) within their study center. The age at which C95 % of women reported having a natural menopause was 58 for NHW and 56 for Hispanics from the 4-CBCS, 55 for NHW and 56 for Hispanics from the SFBCS, and 54 for the MBCS. Race/ ethnicity was self-reported for 4-CBCS and SFBCS; all women from MBCS were considered Hispanic ethnicity.
Genetic data DNA was extracted from available whole-blood (n = 7,287) or saliva (n = 634) samples. Whole-genome amplification (WGA) was applied to the saliva-derived DNA samples prior to genotyping. A tagSNP approach was utilized to characterize variation across the candidate gene. TagSNPs were selected using the following parameters: (1) Linkage disequilibrium (LD) blocks were defined using a Caucasian LD map and an r 2 = 0.8 [41] ; (2) minor allele frequency (MAF) [0.1; (3) range ±1,500 base pairs from the initiation codon or termination codon; and (4) 1 SNP/LD bin [28] . Variants within 3 kb were included to capture the majority of the regulatory region of the CYP19A1 gene. This approach is similar to one employed by Stram et al. [42] , which was based on the genotyping of a high density of SNPs selected every 3-5 kb in and surrounding a candidate gene. Additionally, 104 ancestry informative markers (AIMs) were used to distinguish European and NA ancestry [28, 43] . All markers were genotyped using a multiplexed bead array assay format based on GoldenGate chemistry (Illumina, San Diego, California). A genotyping call rate of 99.93 % was attained (99.65 % for WGA samples). We included 132 blinded internal replicates representing 1.6 % of the sample set. The duplicate concordance rate was 99.996 % as determined by 193,297 matching genotypes among sample pairs [28] . We investigated associations with 25 CYP19A1 tagSNPs: rs4275794, rs4646, rs2899472, rs700518, rs17703883, rs727479, rs10459592, rs12591359, rs12908960, rs7172156, rs11856927, rs2414099, rs17601876, rs2470158, rs730154, rs17523880, rs2470152, rs3751591, rs1902584, rs2445762, rs2470144, rs7174997, rs8025191, rs1961177, and rs6493497. We attempted to capture all of the variation across the CYP19A1 gene using the 25 tagSNPs so that we have active surrogate markers, detecting all variants. These markers should be covering all of the unmeasured variants with 80 % correlation or better. These tag SNPs were chosen based on information obtained HapMap databases and were not supposed to be in high LD with one another. Supplemental Graph 1 includes an LD matrix stratified by ethnicity which shows that LD between SNPs is not high (r 2 \ 0.80) and is similar between ethnic groups for the most part. However, LD differs by ethnic groups for a few SNPs, for example: rs2899472 and rs2470158 are considered to be in high LD within NHW women (r 2 = 0.80), but not within Hispanic/NA women (r 2 = 0.52). Approximately four sets of SNPs (eight total SNPs) were considered to be in very high LD (r 2 [ 0.80) for both ethnic groups.
Tumor characteristics and survival data Data on tumor characteristics and survival were not available for cases from Mexico; therefore, evaluation of these variables was limited to data (available through Spring 2012) obtained from 4-CBCS and SFBCS. Statewide cancer registries in Arizona, Colorado, New Mexico, Utah, and California provided information on stage at diagnosis, ER and PR tumor status, months of survival after diagnosis (calculated as difference between diagnosis date and date of death or last follow-up), and primary cause of death (International Classification of Diseases, 10th Revision) [44] .
Statistical methods
The program STRUCTURE 2.0 was utilized to calculate individual proportion of genetic ancestry based on two founding populations (European and NA) [28, 45] . Participants were classified by level of percent NA ancestry, which was categorized based on the distribution of NA ancestry in the control population. Percent NA ancestry was evaluated by three groups (low\29 %, moderate 29 to B70 %, and high [70 %), to allow sufficient power to assess associations of ancestral groups with breast cancer risk and mortality as previously described [28] . Findings are presented by two NA ancestry groups (\29 %, C29 %) because most of the estimates for breast cancer risk and mortality are not divergent for moderate or high NA ancestry groups; thus increasing power for this group.
Descriptive statistics were calculated for all covariates by level of percent NA ancestry and case-control status, and chi-square (v 2 ) tests were used to assess differences between groups. Minor allele frequencies (MAF) and Hardy-Weinberg equilibrium (HWE) p values were calculated based on the frequencies of alleles and genotypes in the control population. Unconditional multivariable logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for breast cancer risk associations with SNPs. SNPs were further evaluated for their association with breast cancer risk by strata of race/ ethnicity, NA ancestry, menopausal status, HT use (never, ever, former, current), and OC use (never, ever) for all women. Risk of developing a particular breast cancer subtype based on ER/PR tumor phenotype) was evaluated using multinomial logistic regression [46, 47] for the 4-CBCS and SFBCS.
Initially, a co-dominant mode of inheritance was used to determine the relationship between number of alleles expressed and risk of breast cancer or breast cancer death. The assumed co-dominant mode of inheritance allowed us to evaluate whether there was a trend toward a dominant or recessive genetic model, and whether there was power to collapse genotype groups. SNPs were also assessed as continuous variables, and linear trend p values for the overall model (and within strata) were reported. All models were evaluated, and the most appropriate models for each SNP were selected for subsequent analyses. Confounding by categories of body mass index, first-degree family history of breast cancer, menopausal status, parity, OC use, HT use, alcohol consumption, and smoking status, continuous measures of physical activity and NA ancestry were evaluated. Covariates were considered confounders if the univariate p value was B0.20 and adjustment produced a change of C10 % in the effect estimate for the overall association of the genotype with breast cancer risk [48] . We did not observe confounding by any factor assessed. However, all models were adjusted for matching variables of age and study center as well as by NA ancestry. For stratified analyses, tests for interactions were calculated using a one degree of freedom (1 df) likelihood ratio test for logistic regression models with and without an interaction term. All cases (in situ and invasive) and controls were included in the analysis of breast cancer risk (n = 7,733). Sensitivity analysis restricted to only invasive cancers was not conducted because it would limit power as well as comparisons to the estimates including all women, because stage of disease is not available for MBCS participants.
For survival analyses, associations between SNPs and breast cancer mortality were evaluated using multivariable Cox proportional hazard models to obtain hazard ratios (HRs) and 95 % CIs adjusted for SEER summary stage at diagnosis (local, regional, and distant), age, NA ancestry, and study center. Participants were censored if lost to follow-up or died of cause other than breast cancer. Stratified analyses were conducted to determine the presence of effect modification by race/ethnicity, NA ancestry, and menopausal status and assessed using p values from 1 df likelihood ratio tests. Invasive cases from 4-CBCS and SFBCS with available data for survival and stage were included in the survival analysis (n = 2,218).
p values from linear trend tests and interactions in overall models and within stratum were adjusted for multiple comparisons (MCs) within each gene using a stepdown Bonferroni correction method [49] . This method takes into account the correlation of the data using the SNP spectral decomposition method based on the eigenvalues of the correlation matrix among the SNPs for each gene as proposed by Nyholt [50] and modified by Li and Ji [51] . The effective number of independent SNPs is determined and used when adjusting for MC, rather than total SNP number. This method is conservative, especially when evaluating correlated variables such as SNPs within a gene. However, it is less conservative than the conventional Bonferroni correction because you have more opportunities to reject the null hypotheses, which results in an increase in statistical power [51] . An adjusted p B 0.05 (a = 0.05) for main effects and interactions was considered statistically significant. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Breast cancer cases included in this study were predominantly postmenopausal (59.7 %) and between the ages of 40-59 years of age (58.7 %) ( Table 1 ). Compared to women with low NA ancestry (\29 %), cases and controls, respectively, with moderate to high NA ancestry (C29 %) had a higher proportion of premenopausal status (40.3 and 39.9 vs. 33.6 and 31.5 %), a low proportion tended to report ever use of HT (27.5 and 25.6 vs. 53.4 and 54.0 %) and OC (54.1 and 52.8 vs. 69.6 and 64.9 %), and cases more frequently presented with ER-/PR-tumors (17.4 vs. 13.2 %) and regional stage of disease (38.9 vs. 29.8 %). Majority of cases and controls with low NA ancestry were NHW ethnicity (83.7 and 85.0 %, respectively), whereas cases and controls with moderate to high NA ancestry were predominantly Hispanic/NA ethnicity (99.4 and 99.7 %, respectively). A similar proportion of breast cancer cases were deceased in low NA ancestry (15.8 %) and moderate to high NA ancestry (16.3 %), and majority of deaths were due to breast cancer (56.6 and 62 %, respectively) (data not shown in table). Table 2 provides a description of the selected SNPs. CYP19A1 (rs700518) is located in exon 3; both rs4646 and rs4275794 are located in the 3 0 -untranslated region (c).
Associations with breast cancer risk
When considering all women combined, we did not observe any significant associations between the 25 tagSNPs on CYP19A1 and breast cancer risk after MC adjustment. Prior to MC adjustment, one SNP (rs4646) was inversely associated with breast cancer risk for all women (OR AA 0.87, 95 % CI 0.77-0.98) ( Table 3) . Results stratified by NA ancestry were divergent between women with low (\29 %) or moderate to high (C29 %) NA ancestry for several SNPs. We observed inverse associations (OR 0.64-0.82) for the variant alleles in three SNPs (rs10459592, rs1961177, and rs6493497) and positive associations (OR 1.20-1.67) for variant alleles in five SNPs (rs4275794, rs2899472, rs700518, rs12908960, and (Table 4) . However, tests of interaction were not statistically significant for any of these SNPs after MC adjustment. Analyses stratifying by menopausal status showed no statistical significant associations after MC adjustment.
Discussion
We examined the associations between 25 tagSNPs in CYP19A1, a gene involved in the biosynthesis of estrogen, and breast cancer risk and mortality among Hispanic/NA and NHW women taking into account the proportion of NA ancestry. We also evaluated associations taking into account breast cancer subtypes defined by ER/PR status, menopausal status, and possible gene by environment interactions considering HT and OC use. None of the SNPs remained significantly associated with breast cancer risk after MC adjustment. However, many associations tended to differ by NA ancestry groups and two SNPs (rs700518 and rs11856927) remained associated with a slightly increased risk of breast cancer among women with moderate to high NA ancestry; these associations withstood MC adjustments. There was one significant interaction with menopausal status (rs2470144) in which risk was increased for postmenopausal women only. Generally, there were no distinct associations when considering breast cancer subtypes defined by ER/PR, or interactions with HT or OC use. None of the SNPs remained significantly associated Bold text designates significant trend associations at the 0.05 level after adjustment for multiple comparisons a Odds ratios (ORs) adjusted for age, study center, and Native American ancestry b Odds ratios adjusted for age and study center c Wald p value for 1 df test for interaction between SNP*Native American ancestry; p value adjusted for multiple comparisons (BonferroniHolm) in parentheses with breast cancer mortality overall or when stratified by NA ancestry after MC adjustment. The CYP19A1 gene encodes for aromatase, a 503-amino acid protein containing nine coding exons, is found to be expressed in breast tissue, and is also the source of local estrogen production in breast tumors [52] . The expression of CYP19A1 is regulated by tissue-specific promoters which differ between normal breast tissue and breast cancer tissue. The switch in promoters alters plasma estrogen levels that influence estrogen levels in normal breast tissue and breast cancer tissue and are related to increased risk of breast cancer [7, 10] . Due to the fact that the majority of breast cancers are hormone receptor positive and driven by the ER signaling pathway, genetic variation of genes involved in regulation of hormone production is hypothesized to be a plausible factor in breast cancer susceptibility and survival.
Generally, epidemiology studies including predominantly NHW populations have found that genetic variants in CYP19A1 do not have a strong effect on breast cancer risk, regardless of study design (case-control vs. cohort, tagSNP vs. haplotype approach) [10, 11, 13, 15, [17] [18] [19] [20] [53] [54] [55] [56] [57] [58] [59] . Some studies found associations among subgroups, for example: NHW premenopausal women and ER-tumor status [53] , and Japanese women with ER? premenopausal breast cancer [59] . One study found a significant increase in endogenous estrogen levels associated with several SNPs in NHW postmenopausal women [13] . Diergaarde et al. [60] evaluated an interaction between several CYP19A1 polymorphisms and HT use and did not find any significant associations in a NHW population, similar to our findings in this genetically admixed population. Furthermore, several studies [21] [22] [23] [24] [25] [26] have examined genetic variation on CYP19A1 and risk of breast cancer mortality, although findings are mixed. For example, Long et al. [22] found an increased risk of breast cancer mortality for five CYP19A1 SNPs in a Chinese population, while Fasching et al. [21] found an inverse relationship for one SNP (rs10046) and Udler et al. [23] did not find associations with four CYP19A1 SNPs in a NHW population. This study does not provide conclusive evidence that genetic variation in CYP19A1 is a prognostic factor for breast cancer mortality, or that NA ancestry modifies the association.
To our knowledge, the three tagSNPs we found associated with breast cancer risk in moderate to high NA ancestry (rs700518 and rs11856927) and postmenopausal women (rs2470144) have not been previously evaluated in epidemiology studies. We utilized the program SNAP (SNP Annotation and Proxy Search, Broad Institute) [61] to evaluate whether these three SNPs were in high LD with SNPs reported in previous literature. Pair-wise LD is precalculated based on phased genotype data from the International HapMap Project [62] . CYP19A1 rs11856927 or Table 4 Overall associations between selected variants in CYP19A1 gene with breast cancer mortality, stratified by Native American ancestry, the Breast Cancer Health Disparities Study test; p value adjusted for multiple comparisons (Bonferroni-Holm) in parentheses rs2470144 was not found to be in high LD with previously reported SNPs. CYP19A1 rs700518 and rs10046 are in high LD (r 2 = 0.87) in the CEU population (European ancestry); however, we do not know if it is in high LD in the Mexican ancestry population (MEX). CYP19A1 rs700518 and rs4775936 are also found to be in high LD in both CEU and MEX populations (r 2 = 0.81 and r 2 = 0.87, respectively). CYP19A1 rs10046 (T) and the rs4775936 (A) are reportedly associated with higher levels of circulating estrogen or estrogen to androgen ratios in several studies [10] [11] [12] [13] 15] . Despite this relationship, studies have not consistently found an association between these two SNPS and breast cancer risk [15, 63] . One study found that rs10046 is associated with breast cancer risk in Chinese women [64] . In addition to being in LD with these two SNPs that influence estrogen levels, CYP19A1 rs700518 is located in a coding region (exon 3) and was found to be an 'allelic expression marker'; part of a haplotype that is associated with expression of this aromatase gene [14] . Moreover, CYP19A1 rs700518 has been reported as a predictor of endocrine therapy effectiveness in ER? breast cancer [65] .
Findings from our study indicate that NA ancestry may modify the association between genetic variation in CYP19A1 and breast cancer risk. Two possible explanations for the observed results include: (1) Selected genetic variants in CYP19A1 may be susceptibility loci or surrogates for unmeasured functional variants that are more frequent in women with higher NA ancestry and influence differences in breast cancer risk; and (2) estimated NA ancestry may serve as a genetic component to the difference in breast cancer risk. Additionally, we cannot rule out the possibility of three-way gene-environment interactions with CYP19A1 variants, NA ancestry, and environmental factors, which future research could explain. Further evaluation of genetic variants associated with breast cancer risk that varies in frequency and LD patterns across racial/ ethnic groups is needed and may help to identify regions of the genome associated with breast cancer by ethnic groups [36] . For example, Fejerman et al. used an admixture mapping approach and confirmed that the observed association between genetic ancestry and breast cancer risk and is in part due to admixture signals in genomic regions (6q25 and 11p15) that differ between indigenous European and NA ancestral groups [30] .
This study has several strengths and limitations. This is the first study to evaluate genetic variation on the CYP19A1 gene in Hispanic/NA women and NA ancestry groups. The large sample size allowed us to evaluate different modes of inheritance and to conduct stratified analyses. Nevertheless, power was limited when assessing breast cancer survival and ER/PR status, partly due to lack of data from the MBCS. A strength of the survival analyses conducted is the long follow-up period for 4-CBCS and SFBCS, approximately 8 and 10 years, respectively. When stratifying by NA ancestry, we reported estimates including both Hispanic/NA and NHW in the analyses of breast cancer risk and mortality. We were able to rely on genetic markers to determine ancestry and not assume ancestry based on selfreported race. Moreover, women from Mexico were not asked their race/ethnicity and were all considered Hispanic. Interestingly, that study population includes a small proportion of women with low NA ancestry. Some Hispanics/ NA in 4-CBCS and SFBCS also have low NA ancestry. Additionally, utilizing a tagSNP approach we were able to cover variation across the entire gene; however, this approach resulted in assessment of many SNPs making it difficult to observe significant findings after adjustment for MC, which was conservative and may result in false-negative associations. Lastly, after FDR adjustment, one SNP (rs4646) was found to violate HWE and was kept in analysis because these results indicate that there is a difference in observed genotypes by ethnic groups, which we hypothesize, may be due to biological differences in ancestry and may be informative for future studies including women of NA ancestry.
In conclusion, our unique findings suggest there is a positive association with genetic variants in CYP19A1 and breast cancer risk in women of moderate to high NA ancestry, which was not observed in women with low NA ancestry. The plausible functionality of CYP19A1 rs700518 could justify the association observed in women with moderate to high NA ancestry; however, this finding needs to be replicated. These results strengthen the hypothesis that the proportion of estimated NA ancestry may influence biological pathways, increasing susceptibility to breast cancer.
Registries, under agreement #1U58 DP000807-01 awarded to the Public Health Institute. The 4-Corners Breast Cancer Study was funded by Grants CA078682, CA078762, CA078552, and CA078802 from the National Cancer Institute. The research also was supported by the Utah Cancer Registry, which is funded by contract N01-PC-67000 from the National Cancer 
